**Table 1**. Spearman's correlation coefficients-Luminal A carcinoma group. Statistically significant results are highlighted in red color.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **LUMINAL A CARCINOMA** | **GP96****vs****TC** | **GP96 vs CD4** | **GP96 vs CD8** | **CD4** **vs** **IMI** | **CD8 vs IMI** |  | **Relapse** | **Metastasis** | **Pos.ax.l.n.**  | **Death** |
| **GP96 vs TC** | 1.00 |  |  |  |  |  |  |  |  |  |
| **GP96 vs CD4** | 0.42 | 1.00 |  |  |  |  |  |  |  |  |
| **GP96 vs CD8** | 0.63 | 0.51 | 1.00 |  |  |  |  |  |  |  |
| **CD4 vs IMI** | 0.15 | -0.63 | -0.26 | 1.00 |  |  |  |  |  |  |
| **CD8 vs IMI** | 0.13 | -0.20 | -0.46 | 0.31 | 1.00 |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
| **Relapse** | 0.00 | -0.05 | -0.14 | 0.11 | 0.47 |  | 1.00 |  |  |  |
| **Metastasis** | 0.00 | -0.15 | -0.19 | 0.23 | 0.43 |  | 0.29 | 1.00 |  |  |
| **Pos.ax.l.n.** | 0.00 | 0.02 | -0.13 | -0.03 | 0.38 |  | 0.04 | 0.45 | 1.00 |  |
| **Death** | 0.09 | 0.15 | 0.02 | -0.11 | 0.24 |  | 0.14 | 0.43 | 0.39 | 1.00 |

TC - tumor cells; IMI - immune infiltrate; Pos.ax.l.n.- positive axillary lymph nodes.

Table 2. Spearman's correlation coeficcients-Luminal B HER2- carcinoma. Statistically significant results are highlighted in red color.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **LUMINAL B HER2- CARCINOMA** | **GP96 vs TC** | **GP96 vs CD4** | **GP96 vs CD8** | **CD4 vs IMI** | **CD8 vs IMI** |  | **Relapse**  | **Metastasis** | **Pos.ax.l.n.** | **Death** |
| **GP96 vs TC** | 1.00 |  |  |  |  |  |  |  |  |  |
| **GP96 vs CD4** | 0.20 | 1.00 |  |  |  |  |  |  |  |  |
| **GP96 vs CD8** | 0.45 | 0.50 | 1.00 |  |  |  |  |  |  |  |
| **CD4 vs IMI** | 0.38 | -0.61 | -0.06 | 1.00 |  |  |  |  |  |  |
| **CD8 vs IMI** | 0.24 | -0.38 | -0.66 | 0.34 | 1.00 |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
| **Relapse** | -0.37 | 0.28 | -0.34 | -0.37 | -0.11 |  | 1.00 |  |  |  |
| **Metastasis** | 0.28 | 0.01 | 0.03 | 0.16 | 0.15 |  | -0.22 | 1.00 |  |  |
| **Pos.ax.l.n.**  | -0.22 | -0.07 | -0.21 | 0.00 | 0.04 |  | 0.16 | 0.34 | 1.00 |  |
| **Death** | 0.17 | 0.17 | 0.08 | 0.01 | 0.11 |  | -0.04 | 0.44 | 0.39 | 1.00 |

TC - tumor cells; IMI - immune infiltrate; Pos.ax.l.n.- positive axillary lymph nodes.

**Table 3.** Spearman's correlation coefficients-Luminal B HER2+ carcinoma. Statistically significant results are highlighted in red color.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **LUMINAL B HER2+ CARCINOMA** | **GP96 vs TC** | **GP96 vs CD4** | **GP96 vs CD8** | **CD4 vs IMI** | **CD8 vs IMI** |  | **Relapse** | **Metastasis** | **Pos.ax.l.n.** | **Death** |
| **GP96 vs TC** | 1.00 |  |  |  |  |  |  |  |  |  |
| **GP96 vs CD4** | 0.62 | 1.00 |  |  |  |  |  |  |  |  |
| **GP96 vs CD8** | 0.36 | 0.70 | 1.00 |  |  |  |  |  |  |  |
| **CD4 vs IMI** | 0.07 | -0.53 | -0.42 | 1.00 |  |  |  |  |  |  |
| **CD8 vs IMI** | 0.14 | -0.31 | -0.81 | 0.42 |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
| **Relapse**  | -0.12 | -0.16 | -0.34 | 0.11 | 0.37 |  | 1.00 |  |  |  |
| **Metastasis** | -0.16 | 0.00 | -0.18 | -0.13 | 0.22 |  | 0.51 | 1.00 |  |  |
| **Pos.ax.l.n.** | 0.07 | 0.05 | -0.04 | -0.17 | 0.12 |  | -0.11 | 0.18 | 1.00 |  |
| **Death** | -0.03 | 0.16 | -0.04 | -0.06 | 0.16 |  | 0.40 | 0.66 | 0.10 | 1.00 |

TC - tumor cells; IMI - immune infiltrate; Pos.ax.l.n.- positive axillary lymph nodes.

**Table 4.** Spearman's correlation coefficients-HER2+ carcinoma. Statistically significant results are highlighted in red color.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **HER2+** | **GP96 vs TC** | **GP96 vs CD4** | **GP96 vs CD8** | **CD4 vs IMI** | **CD8 vs IMI** |  | **Relapse**  | **Metastasis** | **Pos.ax.l.n.**  | **Death** |
| **GP96 vs TC** | 1.00 |  |  |  |  |  |  |  |  |  |
| **GP96 vs CD4** | 0.01 | 1.00 |  |  |  |  |  |  |  |  |
| **GP96 vs CD8** | 0.34 | 0.39 | 1.00 |  |  |  |  |  |  |  |
| **CD4 vs IMI** | 0.42 | -0.78 | 0.07 | 1.00 |  |  |  |  |  |  |
| **CD8 vs IMI** | 0.11 | 0.07 | -0.74 | -0.25 | 1.00 |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
| **Relapse**  | 0.40 | -0.17 | 0.24 | 0.34 | - 0.06 |  | 1.00 |  |  |  |
| **Metastasis** | 0.14 | 0.06 | -0.10 | 0.00 | 0.22 |  | -0.02 | 1.00 |  |  |
| **Pos.ax.l.n.** | 0.18 | 0.11 | -0.13 | 0.02 | 0.29 |  | 0.20 | 0.30 | 1.00 |  |
| **Death** | 0.29 | 0.18 | 0.03 | -0.07 | 0.30 |  | 0.05 | 0.64 | 0.19 | 1.00 |

TC - tumor cells; IMI - immune infiltrate; Pos.ax.l.n.- positive axillary lymph nodes.

**Table 5.** Spearman' s correlation coefficients-TRIPLE NEGATIVE carcinoma. Statistically significant results are highlighted in red color.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **TRIPLE NEGATIVE** | **GP96 vs TC** | **GP96 vs CD4** | **GP96 vs CD8** | **CD4 vs IMI** | **CD8 vs IMI** |  | **Relapse** | **Metastasis** | **Pos.ax.l.n.** | **Death** |
| **GP96 vs TC** | 1.00 |  |  |  |  |  |  |  |  |  |
| **GP96 vs CD4** | 0.56 | 1.00 |  |  |  |  |  |  |  |  |
| **GP96 vs CD8** | 0.77 | 0.52 | 1.00 |  |  |  |  |  |  |  |
| **CD4 vs IMI** | 0.12 | -0.52 | 0.39 | 1.00 |  |  |  |  |  |  |
| **CD8 vs IMI** | -0.11 | 0.44 | -0.45 | -0.96 | 1.00 |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
| **Relapse**  | -0.08 | 0.18 | -0.02 | -0.32 | 0.32 |  | 1.00 |  |  |  |
| **Metastasis** | 0.08 | 0.25 | -0.04 | -0.40 | 0.38 |  | 0.36 | 1.00 |  |  |
| **Pos.ax.l.n.** | 0.16 | 0.42 | 0.22 | -0.12 | 0.12 |  | 0.11 | 0.37 | 1.00 |  |
| **Death** | 0.08 | 0.37 | -0.05 | -0.46 | 0.45 |  | 0.33 | 0.81 | 0.28 | 1.00 |

TC - tumor cells; IMI - immune infiltrate; Pos.ax.l.n.- positive axillary lymph nodes.